Cure8 research brief
Researchers are exploring ways to durably modulate macrophages in ulcerative colitis because persistent pro-inflammatory macrophages sustain tissue inflammation and impair healing.
A nanoparticle that prolongs intracellular drug exposure could lengthen therapeutic benefit and reduce dosing frequency compared with current approaches.
Researchers working on nanoparticle drug delivery, immune-targeted IBD therapies, and macrophage biology; translational clinicians interested in next-generation IBD treatments.
This study reports an experimental orally administrable nanoparticle (OFEN) designed to fuse with macrophages and act as an intracellular drug depot, releasing TNF-α siRNA and curcumin to shift macrophages toward an M2-like, pro-resolving state.
In mouse colitis models (including chronic DSS and a DSS rechallenge), intermittent oral dosing of OFEN improved disease measures and mucosal recovery compared with 5-ASA and a less fusogenic formulation under the reported dosing schedule.
The approach combines sequence-specific knockdown of TNF-α with broader anti-inflammatory/antioxidant effects from curcumin and relies on milk-derived exosome membranes plus a PLGA core to promote gastrointestinal stability, cellular fusion, reduced endolysosomal sequestration, and prolonged intracellular release.
This report is a preclinical, mechanistic study in animal models and cells; it demonstrates proof-of-concept for prolonged macrophage immunomodulation rather than clinical safety or efficacy in humans. It does not provide human dosing, safety, or long-term outcome data.
This is a preclinical basic‑science study reported in ACS Nano (abstract-level structured content). Findings come from cellular assays and mouse colitis models; they do not imply readiness for human use and will require further safety, pharmacology, and clinical testing.
The paper focuses on a specific fusion-enabled nanoparticle platform and compares it to 5‑ASA and a less fusogenic formulation in the described animal models.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Science and Technology Commission of Shanghai Municipality, award 23HC1401200; National Natural Science Foundation of China, award 12532012; National Natural Science Foundation of China, award 82304392; National Natural Science Foundation of China, award 82373825; National Natural Science Foundation of China, award 82430111; National Natural Science Foundation of China, award 82522083; State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, award 2025-KFA-005; SANOFI Scholarship Program; Strategic Priority Research Program of the Chinese Academy of Sciences, award XDB0830000; Strategic Priority Research Program of the Chinese Academy of Sciences, award XDB1260000; Shanghai "Science and Technology Innovation Action Plan" Technical Standard Project, award 24DZ2202600; Science and Technology Innovation Talent System Construction Program of Shaanxi University of Chinese Medicine, award 2023-CXTD-05; Natural Science Foundation of Shanghai, award 25ZR1401382; State Administration of Traditional Chinese Medicine high-level key discipline construction project, award zyyzdxk-2023202
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
Localized rectal delivery of probiotic-derived vesicles combined with mesalamine may offer a way to reduce inflammation and help mucosal healing in ulcerative colitis using a stable, off-the-shelf formulation. This could...
The study presents preclinical data that an orally delivered biotherapeutic (EPICERTIN) promotes epithelial repair and reduces inflammation in a UC-relevant mouse model — a potential step toward therapies that directly...
